Surface modification and characterization of agglomerated metal oxide particles
2013
0 views
0 downloads
Advisor: Prof. Dr. Mustafa Çulha
Abstract (EN)
Metal Oxide nanomaterials (MONMs) attracted enormous attention due to their unique physicochemical properties and are used in many applications including drugs, paints, biomedical devices and development of novel materials. The surface modification of namomaterials (NMs) is an important step to alter their behavior to further benefit from their unique properties in variety of applications. However, the main problem with them in order to work efficiently is their inefficient dispersion in aqueous environments. In this study, we aimed to understand the surface properties of these materials as we attempt to alter the surface chemistry. Surface coating of the NMs with oligonucleotides, carbohydrates and treatment with hydrogen peroxide (H2O2) help them to stabilize as mono-disperse particles in their colloidal suspensions. The characterization of modified MONMs was performed with Raman Spectroscopy, FTIR Spectroscopy and Dynamic Light Scattering (DLS).
Author
Sinan Sabuncu
How to Cite
Sinan Sabuncu (Master Thesis). Surface modification and characterization of agglomerated metal oxide particles, 2013, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)